Patient ID | Age* | Diagnosis | Pretreatment | Resection | Location | Tumor percentage (BRCA mutation frequency) |
OVCA #1 | 65 | Ovarian low-grade serous carcinoma St IVB | – | Metastasis | Greater omentum | 80% |
OVCA #2P | 71 | Ovarian high-grade serous carcinoma St IIIC | – | Primary | Ovary | 70% |
OVCA #2M | Metastasis | Greater omentum | N/A | |||
OVCA #3 | 69 | Ovarian high-grade serous carcinoma St IVB | Paclitaxel-carboplatin (neoadjuvant) | Primary | Ovary | 20% |
OVCA #4 | 50 | Ovarian high-grade serous carcinoma St IIIC | – | Primary | Ovary | 95% |
OVCA #5 | 39 | Ovarian clear cell carcinoma St IVB | – | Primary | Ovary | 80% |
OVCA #6 | 72 | Ovarian clear cell carcinoma St IIIC | – | Primary | Ovary | 90% |
*at date of resection.
BRCA, breast cancer gene; ID, identification; N/A, not assessed; OVCA, ovarian cancer; St, stage.